2019
Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
Stahl M, Bewersdorf J, Giri S, Wang R, Zeidan AM. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica 2019, 105: 102-111. PMID: 31004015, PMCID: PMC6939518, DOI: 10.3324/haematol.2019.219345.Peer-Reviewed Original ResearchMeSH KeywordsAntilymphocyte SerumHumansImmunosuppression TherapyImmunosuppressive AgentsMyelodysplastic SyndromesProspective StudiesConceptsImmunosuppressive therapyProspective cohort studyMyelodysplastic syndromeClinical trialsResponse rateCohort studySystematic reviewLower-risk myelodysplastic syndromesLow-risk MDS patientsDifferent immunosuppressive regimensTransfusion independence rateAnti-thymocyte globulinComplete remission rateRelevant conference proceedingsOverall response rateTreatment of patientsAcute myeloid leukemiaHigh-quality studiesHigh response rateRandom-effects modelWeb of ScienceImmunosuppressive regimensPatient yearsRemission rateAdverse events
2015
The SPEED (sepsis patient evaluation in the emergency department) score
Bewersdorf J, Hautmann O, Kofink D, Khalil A, Abidin I, Loch A. The SPEED (sepsis patient evaluation in the emergency department) score. European Journal Of Emergency Medicine 2015, 24: 170-175. PMID: 26524675, PMCID: PMC5417572, DOI: 10.1097/mej.0000000000000344.Peer-Reviewed Original ResearchConceptsSeptic patientsEmergency Department Sepsis scoreSevere inflammatory response syndromeScoring systemImmune-suppressed stateMortality rateInflammatory response syndromeArea under the curveStratify mortality riskReceiver operating characteristic curveHospital mortality rateSystolic blood pressureEmergency departmentMortality riskAdmission diagnosisPrognostic factorsResponse syndromePrimary outcomeSepsis scoreLaboratory valuesSource of infectionPatient characteristicsStudy populationSpeed scoresBlood pressure